Dobesilic acid
| |
| Names | |
|---|---|
| IUPAC name
2,5-Dihydroxybenzenesulfonic acid
| |
| Other names
Hydroquinonesulfonic acid
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| ECHA InfoCard | 100.001.667 |
| EC Number |
|
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C6H6O5S | |
| Molar mass | 190.17 g·mol−1 |
| Related compounds | |
Other cations
|
Calcium dobesilate |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Dobesilic acid is a chemical compound with the molecular formula C6H6O5S. It is classified as both a phenol and a sulfonic acid.
Uses[edit]
Salts of dobesilic are used as pharmaceutical drugs. The calcium salt, calcium dobesilate, is used as a vasoprotective drug.[1][2] The diethylamine salt, etamsylate, is an antihemorrhagic agent.[3]
References[edit]
- ^ Zhang X, Liu W, Wu S, Jin J, Li W, Wang N (January 2015). "Calcium dobesilate for diabetic retinopathy: a systematic review and meta-analysis". Science China Life Sciences. 58 (1): 101–7. doi:10.1007/s11427-014-4792-1. PMID 25528255.
- ^ Haller H, Ji L, Stahl K, Bertram A, Menne J (2017). "Molecular Mechanisms and Treatment Strategies in Diabetic Nephropathy: New Avenues for Calcium Dobesilate-Free Radical Scavenger and Growth Factor Inhibition". BioMed Research International. 2017: 1909258. doi:10.1155/2017/1909258. PMC 5634607. PMID 29082239.
- ^ Schulte J, Osborne J, Benson JW, Cooke R, Drayton M, Murphy J, et al. (January 2005). "Developmental outcome of the use of etamsylate for prevention of periventricular haemorrhage in a randomised controlled trial". Archives of Disease in Childhood. Fetal and Neonatal Edition. 90 (1): F31–F35. doi:10.1136/adc.2003.035790. PMC 1721806. PMID 15613570.